Elotuzumab (Empliciti), a new immune-stimulating therapy to treat multiple myeloma has been approved

Last Updated on

December 02, 2015 –  The American Food and Drug Administration (FDA) just granted approval for Elotuzumab (Empliciti) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Elotuzumab (Empliciti) is a monoclonal antibody against SLAMF7 that activates the body’s immune system to attack and kill multiple myeloma cells. It is approved in combination with another FDA-approved treatment for multiple myeloma called Lenalidomide (Revlimid) and Dexamethasone (a type of a Corticosteroid). Elotuzumab (Empliciti) is the second monoclonal antibody only approved to treat patients with

CS1 = SLAMF7; Elotuzumab mode of action

CS1 = SLAMF7; Elotuzumab mode of action

multiple myeloma.  Daratumumab (Darzalex) against CD38 is the second approved monoclonal immune-stimulating antibody for the treatment of patients with multiple myeloma; it was just approved  by the FDA earlier this month; Thasso Post had a report on the fact.

The efficacy of Elotuzumab (Empliciti) was tested in a randomized, open-label clinical study of 646 participants whose multiple myeloma came back after, or did not respond to previous treatment. Those taking Elotuzumab (Empliciti) in combination with Lenalidomide (Revlimid) and Dexamethasone experienced a delay in the amount of time before their disease worsened (19.4 months) compared to participants taking a combination of  Lenalidomide (Revlimid) and Dexamethasone (14.9 months) only.. Additionally, 78.5 percent of those taking Elotuzumab (Empliciti) with  Lenalidomide (Revlimid) and Dexamethasone saw a complete or partial shrinkage of their tumors compared to 65.5 percent in those patients taking the combination of   Lenalidomide (Revlimid) and Dexamethasone only.

There are adverse effects also. The most common adverse effects of Elotuzumab (Empliciti) are fatigue, diarrhea, fever (pyrexia), constipation, cough, nerve damage resulting in weakness or numbness in the hands and feet (peripheral neuropathy), infection of the nose and throat (nasopharyngitis), upper respiratory tract infection, decreased appetite and pneumonia.

Of course, in multiple myeloma, any additional treatment option is highly welcomed. Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white blood cell) found in the bone marrow. These cancerous cells multiply, produce an abnormal protein and push out other healthy blood cells from the bone marrow. This disease may result in a weakened immune system, and cause serious bone and kidney problems. The National Cancer Institute (NCI) estimates there will be 26,850 new cases of multiple myeloma and 11,240 related deaths in the United States this year. No wonder then that both patients and treating physicians are looking forward to using the new treatment option in the fight against multiple myeloma. It is expected that Elotuzumab (Empliciti) will be available in other part of the world soon.

See also some comments on both of the two novel therapies for multiple myeloma:

Tags: , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login




avatar
  Subscribe  
Notify of
thassodotcom
Guest
Joseph Gut

Announced on January 29, 2016, the European Medicines Agency (EMA) has recommended granting a marketing authorisation for Empliciti (elotuzumab) for the treatment of multiple myeloma. It is to be used in combination with lenalidomide and the anti-inflammatory medicine dexamethasone for the treatment of patients who have received at least one prior therapy. As usual in such cases, the opinion adopted by the Committee for Orphan Medicinal Products (COMP) at its January 2016 meeting is an intermediary step on Empliciti’s path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision… Read more »

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Descendants of early Europeans and Africans in US carry Native American genetic legacy September 19, 2019
    Many people in the U.S. do not belong to Native American communities but still carry bits of Native American DNA, inherited from European and African ancestors who had children with indigenous individuals during colonization and settlement. In a new study published 19th September in PLOS Genetics, Andrew Conley of the Georgia Institute of Technology and […]
  • IGF1 gene is essential to adult tendon growth, animal study shows September 19, 2019
    Tendon injuries are among the most common injuries seen in athletes at all levels, from weekend warriors to professional basketball players. For those who rupture their tendons, returning to the same level of physical activity they enjoyed before the injury is rare.
  • Researchers create new protocol to improve gene therapy tool production September 19, 2019
    A method to create a faster and lower cost alternative for a gene therapy tool has been developed by Boston University School of Medicine (BUSM) researchers.
  • Genetic variants with possible positive implications for lifestyle September 19, 2019
    A German and British research team lead by Technical University of Munich (TUM) has examined the interplay between genetics, cardiovascular disease and educational attainment in a major population study. Genetic variants which had been linked to educational attainment in other studies were observed in the subjects. The researchers found that these variants also had implications […]
  • Scientists develop new methodology to genetically modify lab mice and human cells September 19, 2019
    A team led by Cedars-Sinai has designed a rapid method to genetically alter laboratory mice and then used this method to produce personalized animal models of pediatric glioma, an aggressive type of malignant brain cancer in children.
Top